38,883 Shares in Sanofi (NASDAQ:SNY) Acquired by Bayesian Capital Management LP

Bayesian Capital Management LP bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 38,883 shares of the company's stock, valued at approximately $1,875,000.

Several other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC bought a new stake in Sanofi during the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. lifted its stake in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Bessemer Group Inc. boosted its position in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi in the fourth quarter valued at about $31,000. Finally, Sierra Ocean LLC bought a new position in Sanofi in the fourth quarter worth about $44,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Stock Up 2.5 %

Sanofi stock opened at $55.44 on Monday. The business's 50-day simple moving average is $54.53 and its two-hundred day simple moving average is $52.03. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $140.06 billion, a PE ratio of 22.27, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the prior year, the firm earned $1.78 earnings per share. Sanofi's revenue for the quarter was down 11.0% on a year-over-year basis. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.